Two startups selected to the third stage of venture kick !
01.07.2014
AlveoliX and Cobalytics are the winners of venture kick’s second stage. They obtained CHF 20’000 of pre-seed capital and are qualified for the next and last stage to win, if they are successful, CHF 100’000 more.
 Michael Felber, founder of Cobalytics
|
 |
 Olivier Guenat, founder of AlveoliX
|
|
Cobalytics
In up to 80% of the cases fire victims perish not from burns but from acute smoke poisoning. For first responders it is crucial to determine the nature and concentration of the different toxins in whole blood on-site, in order to initiate prehospital care. Therefore, Cobalytics is aiming at introducing a multiplex point-of-care testing platform for fire smoke toxins to make one decision less in an emergency situation: Knowing whom and how to treat.
AlveoliX
To help reduce the huge R&D costs of the pharmaceutical industry, AlveoliX proposes an in-vitro model of the lung that closely mimics the biophysical characteristics of the lung, including the mechanical stress induced by the respiration. This model is expected to best predict the effects of respiratory drug candidates in humans and thus reduce the number of candidates to be tested in costly clinical trials.